Viatris Inc
VTRS11.930USD
-0.010-0.08%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.83BMarket Cap
LossP/E TTM
More Details of Viatris Inc Company
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Viatris Inc Info
Ticker SymbolVTRS
Company nameViatris Inc
IPO dateFeb 01, 1973
CEOSmith (Scott A)
Number of employees32000
Security typeOrdinary Share
Fiscal year-endFeb 01
Address1000 Mylan Boulevard
CityCANONSBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code15317
Phone17245141465
Websitehttps://www.viatris.com/en
Ticker SymbolVTRS
IPO dateFeb 01, 1973
CEOSmith (Scott A)
Company Executives of Viatris Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
--
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--
Ms. Theodora (Doretta) Mistras
Ms. Theodora (Doretta) Mistras
Chief Financial Officer
Chief Financial Officer
25.18K
--
Ms. JoEllen Lyons Dillon
Ms. JoEllen Lyons Dillon
Independent Director
Independent Director
--
--
Mr. Mark W. Parrish
Mr. Mark W. Parrish
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Melina E. Higgins
Ms. Melina E. Higgins
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
--
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Brands
2.28B
64.01%
Generics
1.28B
35.99%
By RegionUSD
Name
Revenue
Proportion
Developed markets
2.12B
59.38%
Greater China
588.90M
16.50%
Emerging Markets
555.10M
15.55%
JANZ
305.70M
8.57%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Brands
2.28B
64.01%
Generics
1.28B
35.99%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.14%
T. Rowe Price Associates, Inc.
7.13%
Davis Selected Advisers, L.P.
6.02%
BlackRock Institutional Trust Company, N.A.
5.31%
State Street Investment Management (US)
4.84%
Other
64.56%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.14%
T. Rowe Price Associates, Inc.
7.13%
Davis Selected Advisers, L.P.
6.02%
BlackRock Institutional Trust Company, N.A.
5.31%
State Street Investment Management (US)
4.84%
Other
64.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.04%
Investment Advisor/Hedge Fund
28.24%
Hedge Fund
8.77%
Research Firm
2.71%
Pension Fund
1.29%
Sovereign Wealth Fund
1.01%
Bank and Trust
0.85%
Individual Investor
0.27%
Family Office
0.06%
Other
12.75%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1934
987.12M
85.35%
-46.41M
2025Q2
1947
984.91M
83.97%
-87.31M
2025Q1
2006
1.01B
85.93%
-61.76M
2024Q4
2002
1.03B
86.53%
+1.20M
2024Q3
1949
989.28M
82.89%
-66.19M
2024Q2
1967
1.02B
85.33%
-16.59M
2024Q1
1986
997.86M
84.00%
-35.39M
2023Q4
2032
990.53M
82.57%
-31.15M
2023Q3
2044
970.48M
80.90%
-45.34M
2023Q2
2080
963.51M
80.35%
-35.04M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
144.70M
12.41%
+694.66K
+0.48%
Jun 30, 2025
T. Rowe Price Associates, Inc.
76.96M
6.6%
+4.28M
+5.89%
Jun 30, 2025
Davis Selected Advisers, L.P.
66.38M
5.69%
+1.43M
+2.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
61.38M
5.26%
-2.94M
-4.57%
Jun 30, 2025
State Street Investment Management (US)
55.29M
4.74%
-6.17M
-10.04%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
31.26M
2.68%
+10.00M
+47.05%
Jun 30, 2025
Geode Capital Management, L.L.C.
31.23M
2.68%
+52.78K
+0.17%
Jun 30, 2025
Columbia Threadneedle Investments (US)
22.77M
1.95%
+1.16M
+5.38%
Jun 30, 2025
Deerfield Management Company, L.P.
24.02M
2.06%
+32.31K
+0.13%
Jun 30, 2025
Invesco Capital Management LLC
24.15M
2.07%
+928.68K
+4.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares U.S. Pharmaceuticals ETF
4.46%
First Trust NASDAQ Pharmaceuticals ETF
3.81%
Davis Select Worldwide ETF
3.62%
Davis Select US Equity ETF
3.36%
Invesco Pharmaceuticals ETF
2.66%
State Street SPDR S&P Pharmaceuticals ETF
2.64%
Invesco S&P Ultra Dividend Revenue ETF
2.56%
Alps Sector Dividend Dogs ETF
2.1%
AAM S&P 500 High Dividend Value ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.88%
View more
iShares U.S. Pharmaceuticals ETF
Proportion4.46%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.81%
Davis Select Worldwide ETF
Proportion3.62%
Davis Select US Equity ETF
Proportion3.36%
Invesco Pharmaceuticals ETF
Proportion2.66%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.64%
Invesco S&P Ultra Dividend Revenue ETF
Proportion2.56%
Alps Sector Dividend Dogs ETF
Proportion2.1%
AAM S&P 500 High Dividend Value ETF
Proportion1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.88%
Dividend
A total of
2.13B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 04, 2025
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 15, 2025 going ex on Nov 24, 2025
Nov 24, 2025
Dec 15, 2025
Nov 24, 2025
Aug 05, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 15, 2025 going ex on Aug 22, 2025
Aug 22, 2025
Sep 15, 2025
Aug 22, 2025
May 07, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 16, 2025 going ex on May 23, 2025
May 23, 2025
Jun 16, 2025
May 23, 2025
Feb 27, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 18, 2025
Mar 10, 2025
Nov 05, 2024
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 13, 2024 going ex on Nov 22, 2024
Nov 22, 2024
Dec 13, 2024
Nov 22, 2024
Aug 06, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 13, 2024 going ex on Aug 23, 2024
Aug 23, 2024
Sep 13, 2024
Aug 23, 2024
May 09, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 14, 2024 going ex on May 23, 2024
May 24, 2024
Jun 14, 2024
May 23, 2024
Feb 28, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2024 going ex on Mar 08, 2024
Mar 11, 2024
Mar 18, 2024
Mar 08, 2024
Nov 08, 2023
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 15, 2023 going ex on Nov 22, 2023
Nov 24, 2023
Dec 15, 2023
Nov 22, 2023
Aug 07, 2023
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 15, 2023 going ex on Aug 23, 2023
Aug 24, 2023
Sep 15, 2023
Aug 23, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Viatris Inc?
The top five shareholders of Viatris Inc are:
The Vanguard Group, Inc. holds 144.70M shares, accounting for 12.41% of the total shares.
T. Rowe Price Associates, Inc. holds 76.96M shares, accounting for 6.60% of the total shares.
Davis Selected Advisers, L.P. holds 66.38M shares, accounting for 5.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 61.38M shares, accounting for 5.26% of the total shares.
State Street Investment Management (US) holds 55.29M shares, accounting for 4.74% of the total shares.
The Vanguard Group, Inc. holds 144.70M shares, accounting for 12.41% of the total shares.
T. Rowe Price Associates, Inc. holds 76.96M shares, accounting for 6.60% of the total shares.
Davis Selected Advisers, L.P. holds 66.38M shares, accounting for 5.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 61.38M shares, accounting for 5.26% of the total shares.
State Street Investment Management (US) holds 55.29M shares, accounting for 4.74% of the total shares.
What are the top three shareholder types of Viatris Inc?
The top three shareholder types of Viatris Inc are:
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
Davis Selected Advisers, L.P.
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
Davis Selected Advisers, L.P.
How many institutions hold shares of Viatris Inc (VTRS)?
As of 2025Q3, 1934 institutions hold shares of Viatris Inc, with a combined market value of approximately 987.12M, accounting for 85.35% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.37%.
What is the biggest source of revenue for Viatris Inc?
In FY2025Q2, the Brands business generated the highest revenue for Viatris Inc, amounting to 2.28B and accounting for 64.01% of total revenue.
